Evaluation of RAS gene status in circulating tumor DNA for colorectal cancer patients with RASg gene mutation

Evaluation of RAS gene status in circulating tumor DNA for colorectal cancer patients with RASg gene mutation - Evaluation of RAS gene status in ctDNA for colorectal cancer patients with RASg gene mutation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038575

Enrollment

Registered

2019-11-13

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with histopathologically confirmed unresecable or metastatic colorectal adenocarcinoma 2) Wild-type RAS status 3) Patients with refractory or unable to tolerate agents (fluoropyrimidines, irinotecan, oxaliplatin and bevacizumab), and refractory to anti-EGFR antibodies (cetuximab and panitumumab)

Exclusion criteria

Exclusion criteria: No willingness to sign a written informed consent documen

Design outcomes

Primary

Measure	Time frame
the allele frequency of RAS gene mutation in circulating tumor DNA	—

Countries

Japan

Contacts

Public ContactNaoki Izawa

St. Marianna University School of Medicine Department of Clinical Oncology

n2izawa@gmail.com0449778111

Outcome results